Martin Kaul

4.5k citations

26 papers · 3.4k indexed · 3 hit papers · h-index 20

Impact in

Immunology top 1%
- Psoriasis: Treatment and Pathogenesis
- Immune Response and Inflammation
Dermatology top 0.5%
- Dermatology and Skin Diseases

Papers in

Immunology 18
- Immune Response and Inflammation 6
- Psoriasis: Treatment and Pathogenesis 6
- Immunodeficiency and Autoimmune Disorders 2
Hematology 8
- Autoimmune and Inflammatory Disorders Research 3
- Hematopoietic Stem Cell Transplantation 2

Co-authors: Kim Papp Richard G. Langley Alan Menter Kristina Unnebrink Martin M. Okun Kenneth B. Gordon Stephen K. Tyring Alexa B. Kimball
Journals: Critical Care Medicine (5 papers)Shock (4 papers)Annals of the Rheumatic Diseases (2 papers)Cancer (1 paper)Journal of the American Academy of Dermatology (1 paper)
Partner nations: Germany United States Canada

In The Last Decade

Martin Kaul

26 papers receiving 3.3k citations

Hit Papers

align trajectories log scale

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) 2007 · 559 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2007 British Journal of Dermatology
2007 Journal of the American Academy of Dermatology
2004 Annals of the Rheumatic Diseases

Peers

Countries citing papers authored by Martin Kaul

Since Specialization

Citations

This map shows the geographic impact of Martin Kaul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Kaul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Kaul more than expected).

Fields of papers citing papers by Martin Kaul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Kaul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Kaul. The network helps show where Martin Kaul may publish in the future.

Co-authors

The 25 scholars most cited alongside Martin Kaul, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Martin Kaul Line = papers co-authored together Martin Kaul links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial Annals of the Rheumatic Diseases ·Thomas Dörner, Martin Kaul, Antónia Szántó, Jui-Cheng Tseng, Athena Papas, Ilona Pylvaenaeinen, Malika Hanser, Nasri Abdallah, Andrea Grioni, Aida Santos Da Costa, Enrico Ferrero, P Gergely, Rainer Hillenbrand, Alexandre Avraméas, Bruno Cenni, Richard M. Siegel	2023	22
2	Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions European Journal of Pharmaceutical Sciences ·Hilmar Schiller, Felix Huth, Carole Schuhler, Anton Drollmann, Martin Kaul, Ralph Woessner, Bharti Shah, Wendy Weis, Peter End	2022	4
3	Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial Clinical and Translational Science ·Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamária Jakab, Magdalena Kistowska, Arvind G. Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr, Bruno Cenni	2021	59
4	First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis Journal of the European Academy of Dermatology and Venereology ·Martin Kaul, Philip Jarvis, Izabela Rozenberg, Frank Kolbinger, Franco Di Padova, Claudio Calonder, Pascal Espié, Jean‐Michel Rondeau, Régis Cèbe, Thomas Huber, R. Mussmann, Maher Aassi, Teresa Sligh	2020	24
5	A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis New England Journal of Medicine ·Kristian Reich, Richard G. Langley, Kim Papp, Jean‐Paul Ortonne, Kristina Unnebrink, Martin Kaul, Joaquin Valdes	2011	150
6	Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis Dermatology ·Dennis A. Revicki, Mary Kaye Willian, Alan Menter, Jean‐Hilaire Saurat, Neesha Harnam, Martin Kaul	2008	98
7	Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) British Journal of Dermatology ·J.‐H. Saurat, G Stingl, Louis Dubertret, Kim Papp, Richard G. Langley, J.‐P. Ortonne, Kristina Unnebrink, Martin Kaul, A. Camez, (unknown) Hit paper breakdown →	2007	559
8	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial Journal of the American Academy of Dermatology ·Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp Hit paper breakdown →	2007	695
9	Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial Kenneth B. Gordon, Robin R. Blum, Kim Papp, Robert Matheson, Chantal Bolduc, Tiffani K. Hamilton, Michael Heffernan, Alan Menter, Martin M. Okun, Judy Zhong, Martin Kaul, Anne Camez	2007	20
10	Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* Critical Care Medicine ·Edward A. Panacek, John C. Marshall, Timothy E. Albertson, David H. Johnson, Steven B. Johnson, Rodger D. MacArthur, Mark Miller, William Barchuk, Steven Fischkoff, Martin Kaul, Leah Teoh, Lori Van Meter, Lothar Daum, Stanley Lemeshow, Gregory A. Hicklin, Christopher J. Doig	2004	267
11	Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Annals of the Rheumatic Diseases ·L.B.A. van de Putte, Catherine Atkin, Michel Malaise, J Sany, Anthony S. Russell, P L C M van Riel, Loukas Settas, J. W. J. Bijlsma, S Todesco, Maxime Dougados, Peter Nash, Paul Emery, Nike Walter, Martin Kaul, Steven Fischkoff, H. Küpper Hit paper breakdown →	2004	512
12	Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study Critical Care Medicine ·Konrad Reinhart, T. Menges, Bengt Gårdlund, Jan H. Zwaveling, Mark Smithes, Jean‐Louis Vincent, José M. Tellado, Antonio Salgado-Remigio, Reuven Zimlichman, Stuart Withington, Klaus Tschaikowsky, Rainer Brase, Pierre Damas, H. Küpper, J. Kempeni, Juergen Eiselstein, Martin Kaul	2001	180
13	Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines Critical Care Medicine ·Klaus Tschaikowsky, Stefan Sđner, Natascha Lehnert, Martin Kaul, J. Ritter	2000	61
14	Relationship between Interleukin‐6 Plasma Concentration in Patients with Sepsis, Monocyte Phenotype, Monocyte Phagocytic Properties, and Cytokine Production Clinical Infectious Diseases ·Andreas Spittler, Martina Razenberger, H. Küpper, Martin Kaul, Werner O. Hackl, George Boltz‐Nitulescu, R. Függer, Erich Roth	2000	93
15	Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock Critical Care Medicine ·Konrad Reinhart, Carola Wiegand-Lohnert, Friedrich Grimminger, Martin Kaul, Stuart Withington, David Treacher, J. Eckart, Sheila M. Willatts, Carmen Bouza, Dietmar Krausch, Felix Stockenhuber, Jurgen Eiselstein, Lothar Daum, J. Kempeni	1996	245
16	HEMOSTATIC PARAMETERS IN SEPSIS PATIENTS TREATED WITH ANTI-TNF±-MONOCLONAL ANTIBODIES Shock ·Christoph Salat, Peter Boekstegers, Ernst Holler, Karl Werdan, Srigitte Reinhardt, Susanne Fateh-Moghadam, Rudolf Pihusch, Martin Kaul, T. Beinert, Erhardt Hiller	1996	14
17	Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F) Blood ·Ernst Holler, HJ Kolb, J. Mittermüller, Martin Kaul, Georg Ledderose, Thomas Duell, Beata Seeber, Michael Schleuning, R. Hintermeíer-Knabe, Birgit Ertl‐Wagner	1995	159
18	REPEATED ADMINISTRATION OF A F(ab′)2 FRAGMENT OF AN ANTI-TUMOR NECROSIS FACTOR α MONOCLONAL ANTIBODY IN PATIENTS WITH SEVERE SEPSIS Shock ·Peter Boekstegers, Stephan Weidenhöfer, R. Zell, Günter Pilz, Ernst Holler, Wolfgang Ertel, Thomas Kapsner, Heinz Redl, G. Schlag, Martin Kaul, J. Kempeni, Roswitha Stenzel, Karl Werdan	1994	24
19	A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer Cancer ·Markus W. Büchler, Helmut Frieß, Karl-Heinz Schultheiss, C Gebhardt, R. Kübel, K. H. Muhrer, M. Winkelmann, Theo Wagener, R Klapdor, Martin Kaul, Gunther Müller, Gregor Schulz, H. G. Beger	1991	69
20	Immunofluorescence of the acetylcholine receptor in endplates Pflügers Archiv - European Journal of Physiology ·Martin Kaul, H. J. Hammer, Raimund Sterz, K. Peper	1982	2

About Martin Kaul

Martin Kaul is a scholar working on Immunology, Hematology, Dermatology, Complementary and Manual Therapy and Epidemiology, having authored 26 papers that have together received 3.4k indexed citations. Recurring topics across this work include Sepsis Diagnosis and Treatment (9 papers), Dermatology and Skin Diseases (6 papers), Immune Response and Inflammation (6 papers), Psoriasis: Treatment and Pathogenesis (6 papers), Chronic Lymphocytic Leukemia Research (3 papers), Autoimmune and Inflammatory Disorders Research (3 papers), Immunodeficiency and Autoimmune Disorders (2 papers) and Hematopoietic Stem Cell Transplantation (2 papers). The work is most often cited by research in Immunology (2.1k citations), Dermatology (868 citations), Hematology (648 citations), Rheumatology (740 citations) and Critical Care and Intensive Care Medicine (207 citations). Martin Kaul has collaborated with scholars based in Germany, United States and Canada. Frequent co-authors include Kim Papp, Richard G. Langley, Alan Menter, Kristina Unnebrink, Martin M. Okun, Kenneth B. Gordon, Stephen K. Tyring, Alexa B. Kimball, Craig L. Leonardi and Bruce Strober. Their work appears in journals such as Critical Care Medicine, Shock, Annals of the Rheumatic Diseases, Cancer and Journal of the American Academy of Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact